Satsuma Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Satsuma Pharmaceuticals, Inc. - overview
Established
2016
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2016 by President and CEO John Kollins, Satsuma Pharmaceuticals, Inc. aka Satsuma Pharmaceuticals, operates as a biopharmaceutical company that develops STS101, that is a novel and proprietary investigational drug-device combination product specifically designed to allow intranasal administration of the anti-migraine drug dihydroergotamine (DHE). The company is a publicly-traded company on NASDAQ by STSA and the employee count was 21. In April 2019, Satsuma Pharmaceuticals, Inc.
raised USD 62 million in series B funding led by Wellington Management Company, with participation from Osage University Partners, CAM Capital, Surveyor, Eventide Asset Management, Cormorant, Lumira Ventures, and SBI Investment. RA Capital Management, TPG Biotech, and Shin Nippon Biomedical Laboratories also participated in the round. The company develops STS101 which is prepared by combining Satsuma powder technology with a nasal delivery device that is used for acute treatments for migraine. The firm offers a proprietary dry-powder formulation that is a mucoadhesive drug carrier and engineered drug particle technologies.
Satsuma Pharmaceuticals provide a nasal delivery device that is its proprietary product. STS101 is evaluated in Phase 3 clinical trials for the acute treatment of migraine.
Current Investors
TPG Biotech, RA Capital Management, Shin Nippon Biomedical Laboratories, LTD.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.satsumarx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Satsuma Pharmaceuticals, Inc. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - |
| EBITDA (USD) | (5,200,000) | (7,300,000) | (28,867,000) | - | - | - |
| Operating Income (USD) | (5,200,000) | (7,300,000) | (28,881,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - |
| NET Income (USD) | (5,200,000) | (7,400,000) | (28,175,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - |
Satsuma Pharmaceuticals, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.